Biotechnology · Healthcare
Head of Investor Relations
Analyst
LifeSci Advisors
Head of Investor Relations
Mineralys Therapeutics, Inc. (MLYS)Head of Investor Relations
Viridian Therapeutics, Inc.\DE (VRDN)Equibles does not estimate personal net worth.
Dan Ferry is recorded as Analyst at LifeSci Advisors, Head of Investor Relations at Mineralys Therapeutics, Inc. (MLYS) and Head of Investor Relations at Viridian Therapeutics, Inc.\DE (VRDN). Dan Ferry has spoken on 24 earnings calls across 4 companies, most recently for Mineralys Therapeutics, Inc. on November 4, 2026. Those appearances were for CorMedix Inc. (CRMD), Mineralys Therapeutics, Inc. (MLYS), X4 Pharmaceuticals, Inc (XFOR) and Rain Enhancement Technologies Holdco, Inc. (RAIN). Mineralys Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Viridian Therapeutics, Inc.\DE is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Dan Ferry spoke on are classified in the Healthcare and Industrials sectors. Other leadership on record at Mineralys Therapeutics, Inc. includes Jon Congleton (CEO and Board Member), Glenn P. Sblendorio (Chairman), Alexander Gold (Board Member) and 6 others.
“I would like to welcome everyone joining us today for our third quarter 2026 conference call. This afternoon, after the close of market trading, we issued a press release providing our third quarter 2026 financial results and business updates.”
“I would like to welcome everyone joining us today for our second quarter 2026 conference call. This afternoon, after the close of market trading, we should have a press release providing our second quarter 2026 financial results and business updates.”
“I would like to welcome everyone joining us today for our fourth quarter and full year 2025 conference call. This afternoon, after the close of market trading, we issued a press release providing our fourth quarter and full year 2025 financial results and business updates.”
“Presenting on today's call will be X4's Chief Executive Officer, Dr. Paula Ragan; and Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions, and will be joined by Chief Commercial Officer, Mark Baldry; and Chief Medical Officer, Dr. Christophe Arbet-Engels.”
“Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix.”
LifeSci Advisors
Analyst
Source not stated
Biotechnology · Healthcare
Head of Investor Relations
Biotechnology · Healthcare
Head of Investor Relations
CRMD
Biotechnology · Healthcare
Pollution & Treatment Controls · Industrials